Journal: Neurology and Therapy

Article Title: Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate

doi: 10.1007/s40120-021-00298-5

Figure Lengend Snippet: Clinical characteristics of the patients with NMOSD receiving rituximab, azathioprine, or mycophenolate mofetil treatment according to seropositive and seronegative AQP4-Ab status

Article Snippet: Rituximab (RTX), azathioprine (AZA), and mycophenolate mofetil (MMF) are effective, with significant improvements in the Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR), regardless of the seropositive or seronegative aquaporin-4 antibody status..

Techniques:

Journal: Neurology and Therapy

Article Title: Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate

doi: 10.1007/s40120-021-00298-5

Figure Lengend Snippet: Changes of EDSS ( a ) and ARR ( b ) after RTX, AZA, and MMF treatment versus pre-treatment. There was no statistically significant difference among the three groups ( P > 0.05). EDSS Expanded Disability Status Scale, ARR annualized relapses rate, RTX rituximab, AZA azathioprine, MMF mycophenolate mofetil

Article Snippet: Rituximab (RTX), azathioprine (AZA), and mycophenolate mofetil (MMF) are effective, with significant improvements in the Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR), regardless of the seropositive or seronegative aquaporin-4 antibody status..

Techniques:

Journal: Neurology and Therapy

Article Title: Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate

doi: 10.1007/s40120-021-00298-5

Figure Lengend Snippet: Kaplan–Meier survival estimates pertaining to probabilities of being without relapse after RTX (rituximab, top line), AZA (azathioprine, middle line), and MMF (mycophenolate mofetil, bottom line) treatment. Kaplan–Meier survival estimates indicated significant differences in relapse rates between RTX- and AZA-treated subjects, and in relapse rates between RTX- and MMF-treated subjects, but not significant difference in relapse rates between MMF- and AZA-treated subjects. Namely, RTX-treated patients were more likely to be relapse-free after long-term follow-up than those who received AZA or MMF therapy (log rank p < 0.05)

Article Snippet: Rituximab (RTX), azathioprine (AZA), and mycophenolate mofetil (MMF) are effective, with significant improvements in the Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR), regardless of the seropositive or seronegative aquaporin-4 antibody status..

Techniques:

Journal: Neurology and Therapy

Article Title: Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate

doi: 10.1007/s40120-021-00298-5

Figure Lengend Snippet:

Article Snippet: Rituximab (RTX), azathioprine (AZA), and mycophenolate mofetil (MMF) are effective, with significant improvements in the Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR), regardless of the seropositive or seronegative aquaporin-4 antibody status..

Techniques: